Human Growth Factor II Kit

Application(s)		Cardiovascular
Analyte(s)		SCFR/Kit, VEGFR-2/KDR
Species		Human
Instrument(s)		SECTOR Imager 2400 , MESO SECTOR S 600MM , SECTOR Imager 6000 , MESO QuickPlex SQ 120MM , MESO QuickPlex SQ 120 , MESO SECTOR S 600
Plate Type		96-well
Capture Antibody		c-Kit: Mouse Monoclonal VEGFR-2 (KDR): Mouse Monoclonal
Detection Antibody		c-Kit: Goat Polyclonal VEGFR-2 (KDR): Goat Polyclonal
LLOD (Sensitivity)		c-Kit: 116 pg/mL VEGFR-2 (KDR): 2.0 pg/mL
Dynamic Range		c-Kit: 116-150000 pg/mL VEGFR-2 (KDR): 2.0-15000 pg/mL
Sample Type		Serum, Plasma
Recombinant standards		c-Kit: Recombinant Human c-Kit expressed in Sf 21 cells using a baculovirus expression system VEGFR-2 (KDR): Recombinant Human sKDR producued as a non-chimeric protein in a monomeric form
Usage Statement		For Research Use Only. Not for use in diagnostic procedures.
Storage Statement(s)		Please refer to the product insert for the storage conditions of individual kit components.
Storage Condition		Multi-Component
Schedule B Code		3002.15.0100

Product Inserts		Human Growth Factor II
Datasheets		DS Human Growth Factor II
SDS		Blocker A Diluent 10, Diluent 11, Diluent 12, Diluent 13, Diluent 15, Diluent 16 and Diluent 17 MSD Calibrators and Controls Phosphate Buffer (5x) Read Buffer T (4x), Read Buffer S (4x) and Read Buffer S (1x)

Title	Journal	Year
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rúa SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT.	Ann Oncol	2013
Placental Growth Factor and Soluble c-Kit Receptor Dynamics Characterize the Cytokine Signature of Imatinib in Prostate Cancer and Bone Metastases. Mathew, P., Wen, S., Morita, S., Thall, P.F.	J Interferon Cytokine Res.	2011
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. Mathew, P., Wen, S., Morita, S., Thall, P.F.	J Interferon Cytokine Res.	2011
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Fujisaka, Y., Yamada, Y., Yamamoto, N., Shimizu, T., Fujiwara, Y., Yamada, K., Tamura, T., Watanabe, H., Sun, Y.N., Bass, M.B., Seki, M.	Cancer Chemother Pharmacol.	2010

Please Sign In